Navigation Links
New malaria vaccine shows promise in early clinical trial

A malaria vaccine remains the most desired tool to combat the worsening malaria epidemic in many developing countries. Pierre Druilhe and colleagues (from the Institut Pasteur in Paris) have completed the first human trial of a vaccine based on MSP3, a protein present on the surface of the malaria parasite, with very encouraging results.

As the researchers report in the international open-access medical journal PLoS Medicine, most of the 30 healthy volunteers who received the vaccine developed strong, specific, and in some cases long-lasting immune responses against the MSP3 protein.

However, as researchers have learned from many early HIV and malaria vaccine trials, the crucial question is whether these immune responses mean that vaccinated people are actually protected against malaria. The straightforward way to test this is to expose the vaccinated trial participants to malaria and see if they are protected. However, this risky test is not ethical during the early stages of vaccine testing.

But Druilhe and colleagues were nevertheless able to take their early trial a step further: They demonstrated that antibodies from the blood of vaccinated volunteers were able to inhibit growth of the malaria parasite in two independent laboratory assays.

"A particular strength of the MSP3 trial is that functional assays [tests to see whether the vaccine could kill parasites] were utilized to assess the quality of the antibody response produced," say Brendan Crabb and James Beeson in an accompanying Perspective. However, they also point out that important questions remain, some of which will only be answered in additional clinical trials. Based on the results described in the PLoS Medicine article, Druilhe and colleagues have started a Phase II efficacy field trial of the MSP3 vaccine in malaria-exposed individuals.


'"/>

Source:Public Library of Science


Page: 1

Related biology news :

1. Scientists reveal molecular secrets of the malaria parasite
2. Simple drug has the potential to save many lives threatened by malaria
3. Molecular models advance the fight against malaria
4. Reducing malarial transmission in Africa
5. Sickle cell and protection against malaria
6. Chemists synthesize molecule that helps body battle cancers, malaria
7. Gene expands malarias invasion options
8. University of Nevada, Reno research team discovers hormone that causes malaria mosquito to urinate
9. Measuring hidden parasites in falciparum malaria
10. Old drug, new tricks: Prospects for slashing the impact of malaria
11. Researchers discover how malaria parasite disperses from red blood cells
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/20/2016)... , May 20, 2016  VoiceIt is ... partnership with VoicePass. By working together, ... experience.  Because VoiceIt and VoicePass take slightly different ... engines increases both security and usability. ... excitement about this new partnership. "This ...
(Date:5/9/2016)... Elevay is currently known as ... for high net worth professionals seeking travel for work ... world, there is still no substitute for a face-to-face ... your deal with a firm handshake. This is why ... of citizenship via investment programs like those offered by ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
Breaking Biology News(10 mins):
(Date:5/19/2016)... ... May 19, 2016 , ... KCAS ... welcomed Abu Siddiqui as Director, Large Molecule & Biomarker Bioanalysis. , Dr. Siddiqui ... translational biomarker discovery studies for preclinical and clinical safety programs. “We’ve seen significant ...
(Date:5/18/2016)... 18, 2016 The Biotech industry continues ... mean that there are no opportunities ahead. Today, ActiveWallSt.com has ... THLD ), Seattle Genetics Inc. (NASDAQ: ... Ophthotech Corp. (NASDAQ: OPHT ). Sign up now ... http://www.activewallst.com/ Threshold Pharmaceuticals Inc.,s shares ...
(Date:5/17/2016)... , May 18, 2016 Haselmeier ... prefilled pen following approval by EMA, the European Medicines ... science and technology company, the new pen version includes ... increased level of confidence to patients during use. ... prefilled pen easier to handle with a larger display ...
(Date:5/17/2016)... Switzerland , May 17, 2016 ... company located in Basel, Switzerland ... investigational oral inhibitor of P38 mitogen-activated protein kinase. ... , Strekin will build the necessary ... in indications in which MAP Kinases play fundamental ...
Breaking Biology Technology: